Leerink Partnrs Comments on Cencora’s Q4 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Leerink Partnrs lowered their Q4 2025 EPS estimates for Cencora in a report issued on Monday, October 6th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $3.80 per share for the quarter, down from their previous forecast of $3.81. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Leerink Partnrs also issued estimates for Cencora’s Q1 2026 earnings at $4.09 EPS, Q2 2026 earnings at $4.98 EPS, Q3 2026 earnings at $4.34 EPS, Q4 2026 earnings at $4.17 EPS, FY2027 earnings at $19.43 EPS, FY2028 earnings at $21.36 EPS and FY2029 earnings at $23.60 EPS.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 EPS.

A number of other analysts have also recently commented on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a report on Saturday, September 27th. Wells Fargo & Company raised their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Finally, Jefferies Financial Group increased their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $314.55.

Cencora Stock Performance

Shares of COR stock opened at $308.63 on Tuesday. Cencora has a 12 month low of $219.69 and a 12 month high of $315.23. The stock has a market cap of $59.84 billion, a PE ratio of 31.75, a price-to-earnings-growth ratio of 1.43 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The company’s fifty day moving average price is $295.45 and its 200-day moving average price is $290.80.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio is currently 22.63%.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the transaction, the chief executive officer owned 39,274 shares in the company, valued at approximately $11,389,460. This represents a 11.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock worth $16,292,923 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after purchasing an additional 1,125,661 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Cencora by 8.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares during the period. Wellington Management Group LLP lifted its stake in shares of Cencora by 7.2% in the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after purchasing an additional 363,402 shares during the period. Boston Partners lifted its stake in shares of Cencora by 8.1% in the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after purchasing an additional 404,093 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after purchasing an additional 284,229 shares during the period. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.